Schering Lotrisone Warnings Should Be Milder, FDA Committee Says
Executive Summary
Schering-Plough Lotrisone labeling should sufficiently warn against use of the drug in children under 12 but should not be so severe that physicians who use it off label for valid reasons are intimidated, FDA's Dermatologics & Ophthalmics Advisory Committee said.
You may also be interested in...
FDA Limits Schering Lotrisone Indication, Approves Lotion Formulation
Schering-Plough Lotrisone cream is no longer indicated to treat symptoms of tinea caused by Microsporum canis, following a labeling change.
FDA Limits Schering Lotrisone Indication, Approves Lotion Formulation
Schering-Plough Lotrisone cream is no longer indicated to treat symptoms of tinea caused by Microsporum canis, following a labeling change.
Corticosteroid-Only Arm Worth Public Health Risk In Antifungal Trials - Cmte.
The benefits of studying a stand-alone corticosteroid arm in a trial comparing an antifungal/corticosteroid combination to an antifungal outweigh public health concerns raised by patient exposure to the corticosteroid, FDA's Dermatologics & Ophthalmics Committee concluded.